Gene therapy is offering rare disease patients the promise of delivering potential cures, but as it is generally approached today it has technical challenges to overcome, manufacturing complexities, and an expected high cost. What are “Homology Medicines?” And how are they taking a unique approach to gene therapy? We spoke to Arthur Tzianabos, CEO of Homology Medicines, about what the company has to offer, how it’s unique, and why its production and cost may be similar to other biologics today.
About The Host | Daniel Levine
Daniel S. Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his 25-year career. He founded Levine Media Group in 2013 to provide strategic communications to life sciences companies. He is host of The Bio Report and RARECast podcasts, a senior fellow at the Center for Medicine in the Public Interest, and a member of the advisory board of the California Biotechnology Council.